Publications of the Week

Loss of Aly/ALYREF Suppresses Toxicity in Both Tau and TDP-43 Models of Neurodegeneration

By February 16, 2022No Comments

Read the Publication

This week we profile a recent publication in GeroScience from Dr. Rebecca Kow the laboratory of Dr. Brian Kraemer at UW and the Geriatrics Research Education and Clinical Center.

Can you provide a brief overview of your lab’s current research focus?

The Kraemer lab works to understand the molecular mechanisms of neurodegenerative disease associated with aging. Diseases of emphasis include:

  • Alzheimer’s Disease
  • Frontotemporal Lobar Degeneration
  • Amyotrophic Lateral Sclerosis
  • Progressive Supranuclear Palsy
  • Corticobasal Degeneration
  • Other Alzheimer’s Disease-Related Dementia

What is the significance of the findings in this publication?

The main finding of the study is that we have found an additional family of RNA binding proteins/processing factors in the alyref homologs of C. elegans that modify tau-mediated neurodegeneration. Alyref also modifies TDP-43 proteinopathy in this system. These findings add to the increasing evidence in the field that RNA binding proteins are important modulators of both tau and TDP-43 neurodegenerative diseases. This suggests that defects in RNA processing may be a common pathway for the start and/or the progression of these diseases. Determining the mechanisms in which RNA-interacting proteins modulate tau and TDP-43 may substantially increase our understanding of how tau and TDP-43 can cause neurodegeneration.

What are the next steps for this research?

Our next steps will be to investigate how RNA changes influence tauopathy in model systems and disease.

Read the Publication